Cyfuse Biomedical KK (FSE:4892) ROC (Joel Greenblatt) %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FSE:4892 Cyfuse Biomedical KK FSE:4892
31 GF Score
Price 円527.00
GF Value 円2,172.95
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK ROC (Joel Greenblatt) %?

Cyfuse Biomedical KK FSE:4892 31 ROC (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus rates FSE:4892 with a GF Score™ of 31/100 and a GF Value™ of 円2,172.95. The stock has 5 warning signs investors should review. Among 983 Drug Manufacturers companies, Cyfuse Biomedical KK ranks worse than 90.84% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cyfuse Biomedical KK's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Cyfuse Biomedical KK's ROC (Joel Greenblatt) % or its related term are showing as below:

FSE:4892' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -829.53   Med: -314.6   Max: 247.05
Current: -197.42

During the past 6 years, Cyfuse Biomedical KK's highest ROC (Joel Greenblatt) % was 247.05%. The lowest was -829.53%. And the median was -314.60%.

FSE:4892's ROC (Joel Greenblatt) % is ranked worse than
90.84% of 983 companies
in the Drug Manufacturers industry
Industry Median: 11.46 vs FSE:4892: -197.42

Cyfuse Biomedical KK's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Cyfuse Biomedical KK  (FSE:4892) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Cyfuse Biomedical KK ROC (Joel Greenblatt) % Related Terms


Cyfuse Biomedical KK ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Cyfuse Biomedical KK's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyfuse Biomedical KK ROC (Joel Greenblatt) % Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial 247.05 -271.34 -246.61 -393.54 -357.85

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -288.42 -422.27 0.00 0.00 -354.61

FSE:4892 vs : ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyfuse Biomedical KK ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's ROC (Joel Greenblatt) % falls into.


FSE:4892
31GF Score
Cyfuse Biomedical KK FSE:4892
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyfuse Biomedical KK ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.983 + 59.33 + 104.966) - (45.499 + 0 + 150.585)
=-27.805

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.464 + 88.739 + 73.655) - (133.038 + 0 + 63.361)
=-28.541

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Cyfuse Biomedical KK for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (211.049 + max(-27.805, 0)) + (203.31 + max(-28.541, 0)) )/ 2 )
=0/( ( 211.049 + 203.31 )/ 2 )
=0/207.1795
=0.00 %

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of 0.00% mean?
Cyfuse Biomedical KK (FSE:4892) has a ROC (Joel Greenblatt) % of 0.00% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cyfuse Biomedical KK and its competitors. According to the industry distribution chart, Cyfuse Biomedical KK ranks #893 out of 983 companies in the Drug Manufacturers industry, placing it in the top 90.8%.
Is Cyfuse Biomedical KK's ROC (Joel Greenblatt) % too high?
Cyfuse Biomedical KK's current ROC (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Cyfuse Biomedical KK ranks #893 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cyfuse Biomedical KK has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's ROC (Joel Greenblatt) % compare to ?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #893 out of 983 companies for ROC (Joel Greenblatt) %. This places Cyfuse Biomedical KK in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current ROC (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Cyfuse Biomedical KK (FSE:4892) has a current ROC (Joel Greenblatt) % of 0.00%. The stock's GF Value™ is 円2,172.95, compared to a current price of 円527.00 — trading 75.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 0.00%. Cyfuse Biomedical KK's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Cyfuse Biomedical KK (FSE:4892), the current ROC (Joel Greenblatt) % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyfuse Biomedical KK (FSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円527.00 is trading 75.7% below its estimated GF Value™ of 円2,172.95.

Key valuation signals for FSE:4892:

  • ROC (Joel Greenblatt) %: 0.00%
  • GF Value™: 円2,172.95 vs. price of 円527.00 (75.7% below fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the FSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cyfuse Biomedical KK Business Description

Comparable Companies
Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
31GF Score

Get the complete analysis for FSE:4892

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円527.00
Price
円2,172.95
GF Value